Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Short Interest Down 37.4% in April

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Get Free Report) was the recipient of a significant drop in short interest during the month of April. As of April 15th, there was short interest totalling 141,400 shares, a drop of 37.4% from the March 31st total of 226,000 shares. Based on an average trading volume of 1,400,000 shares, the short-interest ratio is presently 0.1 days. Currently, 1.8% of the shares of the company are short sold.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

An institutional investor recently raised its position in Cumberland Pharmaceuticals stock. Two Sigma Investments LP lifted its position in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Free Report) by 94.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 37,649 shares of the specialty pharmaceutical company's stock after acquiring an additional 18,271 shares during the period. Two Sigma Investments LP owned approximately 0.27% of Cumberland Pharmaceuticals worth $89,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 15.51% of the company's stock.

Cumberland Pharmaceuticals Stock Performance

Shares of NASDAQ:CPIX traded down $0.02 on Thursday, reaching $4.81. 5,078 shares of the company's stock were exchanged, compared to its average volume of 863,149. Cumberland Pharmaceuticals has a twelve month low of $1.04 and a twelve month high of $7.25. The company has a fifty day moving average of $4.80 and a 200-day moving average of $3.16. The company has a market capitalization of $67.19 million, a price-to-earnings ratio of -6.25 and a beta of -0.24. The company has a current ratio of 1.13, a quick ratio of 0.99 and a debt-to-equity ratio of 0.41.

Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last issued its quarterly earnings results on Tuesday, March 4th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter. The company had revenue of $10.44 million for the quarter. Cumberland Pharmaceuticals had a negative return on equity of 9.50% and a negative net margin of 29.54%.

Analyst Ratings Changes

Separately, StockNews.com raised shares of Cumberland Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Thursday, March 6th.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.